Stifel Nicolaus Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price

Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by stock analysts at Stifel Nicolaus from $34.00 to $40.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 70.50% from the company’s current price.

A number of other research analysts have also recently issued reports on NRIX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Tuesday, April 21st. Jefferies Financial Group increased their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a report on Friday. Royal Bank Of Canada lifted their price target on Nurix Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Oppenheimer began coverage on shares of Nurix Therapeutics in a research note on Monday, June 29th. They issued an “outperform” rating and a $28.00 price target on the stock. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.62.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $23.46 on Friday. Nurix Therapeutics has a 1 year low of $8.19 and a 1 year high of $25.08. The firm has a 50-day moving average of $18.31 and a 200 day moving average of $17.33. The stock has a market cap of $2.43 billion, a P/E ratio of -7.54 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). The company had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. Research analysts expect that Nurix Therapeutics will post -2.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the sale, the chief financial officer owned 37,592 shares in the company, valued at $624,027.20. This represents a 27.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the transaction, the insider directly owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. This trade represents a 4.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 25,051 shares of company stock worth $434,466. 6.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. General Atlantic L.P. purchased a new stake in shares of Nurix Therapeutics in the fourth quarter worth about $92,899,000. Morgan Stanley raised its position in Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after purchasing an additional 2,620,323 shares during the last quarter. Rubric Capital Management LP acquired a new stake in Nurix Therapeutics during the 4th quarter worth $46,930,000. Braidwell LP acquired a new stake in Nurix Therapeutics during the 4th quarter worth $41,428,000. Finally, Price T Rowe Associates Inc. MD grew its position in Nurix Therapeutics by 195.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock worth $61,622,000 after purchasing an additional 2,149,268 shares during the last quarter.

Key Nurix Therapeutics News

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix announced a global collaboration with Roche for bexobrutideg that could bring up to $2.3 billion in total payments, including a $700 million upfront payment, which is a major validation of the company’s pipeline and a meaningful source of non-dilutive capital. Article Title
• Positive Sentiment: Needham & Company LLC reaffirmed its Buy rating and set a $34 price target, implying notable upside from recent trading levels. Article Title
• Positive Sentiment: BTIG Research also reiterated a Buy rating with a $32 price target, reinforcing the view that the Roche deal and broader pipeline remain attractive to analysts. Article Title
• Neutral Sentiment: Nurix’s second-quarter results were weaker than expected, with a loss of $0.81 per share versus estimates for a $0.72 loss and revenue of $9.04 million versus $15.29 million expected, highlighting ongoing operating losses and revenue volatility. Article Title
• Neutral Sentiment: Additional coverage of the Q2 2026 earnings release echoed the same miss on EPS and revenue, which may temper enthusiasm but is partly offset by the Roche collaboration and analyst upgrades. Article Title

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.